Author Archives: admin


Our voice here is a moral voice – Martha’s Vineyard Times

The Marthas Vineyard Hebrew Center recently held a forum to discuss how to mitigate the fallout from the recently overturned Roe v. Wade decision by the Supreme Court, and to highlight the chief notion of the discourse advocacy for reproductive justice.

The Hebrew Center cares about this issue, and about pro choice, and abortion justice, began Rabbi Caryn Broitman, from a religious perspective.

Reaching far beyond the particulars of a decision to terminate a pregnancy, Broitman emphasized the need for women to be able to make their own choices concerning their own bodies, and stressed additional need to support the autonomy that comes with a person taking various socially and medically geared avenues.

The Hebrew Centers support for womens reproductive rights is not of political motivation, explained Broitman. Our voice here is a moral voice. It is a life voice. And its a spiritual, religious voice.

Broitman cited Israels ultra orthodox chief rabbi who said publicly in 1948 that theres no legal reason to prevent an abortion.

Jewish value of reproductive justice, said Broitman, is significant; for it is encompassed by the greater need to take care of ones body and ensure health and wellbeing. [Therefore,] women and pregnant people dont need to offer an excuse or reason to justify their abortion. Its our healthcare.

The Womens Centers, a leading organization for abortion care research work including stem cell research sees around 40,000 clients per year and has been a frequent target for anti-abortion terrorism, mainly as a response to its success in womens rights advocacy.

Elizabeth Barnes, former Chappy resident and president of the Womens Centers one of the largest abortioin providers nationwide spoke to the Hebrew Center crowd about her work. Barnes noted that current moment, women from Alabama and Tennessee where abortion has been deemed illegal have been provided access to the procedure through efforts by the organization to transport them to New Jerseys centers.

Barnes harkened back to her early days working for the cause, in a clinic in Pennsylvania, having started the job at the same time that two women, both of whom were her age, and also hailing from New England, were shot and killed in Brooklyn because of their association with a womens clinic.

Following the incident, Barnes said her family questioned her career path, expressing concerns over her safety; but Barnes could not be dissuaded because the work was too important.

Barnes made note that the shooting affirmed that importance, provoking women and supporters of reproductive justice to continue the efforts to maintain health equality. The directed violence, said Barnes, didnt work people persisted.

Barnes said through the evolution of the medicine of abortion, have, overtime, created an incredible community of brilliant thinkers who are saving peoples lives in complex abortion and materntity work, with the caveat of if given the opportunity.

Barnes relayed countless stories of women who have had to face numerous obstacles in their efforts to secure access to noninvasive medical abortions via oral pill, some traveling over 18 hours in order to terminate their five, six, or seven week pregnancy.

Some states, that have not banned abortion fully, still enact absurd waiting periods, in many cases resulting in doubling the amount of weeks a woman remains pregnant.

But, abortion is just part of the story, said Barnes, noting that Roe V. Wade was overturned in the midst of a nationwide diaper and baby formula shortage, further shedding light on the health access disparity women continuously endure.

The United States maternal mortality rate, Barnes said, is horrific, especially among women of color, and regardless of income.

Barnes said that despite abortion being legal in Massachusetts, theres a lot of progress yet to be made including on the Vineyard, which currently lacks access to even early, first trimester abortions. Barnes noted one particular instance, which left a few-weeks-pregnant woman who had already chosen to terminate, pregnant for longer, bringing with it all forms of distress. It begs the question of how a community can enhance its role as a womens health supporter, provider, and safe haven.

Marthas Vineyard is indeed a special place, said Barnes, but we are not special when advocating for abortion work. We need to get on it.

According to Talmudic texts written law and traditions of Judaism Broitman relayed that the essence of life is that which is after birth. Theres no question about it, she said.

Because of this understanding, it is the mothers life that takes precedence; not that of an unborn fetus. Life, explained Broitman, does not equate a fetus or potential life within a persons body to all of life.

Accentuating the traditional view of the importance of womens lives and health, Barnes offered a quote by well-known Rabbi Moses Sofer: No woman should have to save the world by destroying herself.

Continue reading here:
Our voice here is a moral voice - Martha's Vineyard Times

Scientists Unlock the Secrets of Cellular Aging: What Happens After You Turn 70? – SciTechDaily

Researchers have revealed the cellular mysteries behind aging.

A new explanation for aging has been developed by researchers who have shown that genetic abnormalities that develop gradually over a lifetime cause substantial alterations in how blood is generated beyond the age of 70.

According to recent research, the drastic reduction in blood production beyond the age of 70 is likely caused by genetic alterations that steadily accumulate in blood stem cells throughout life.

Researchers from the Wellcome Sanger Institute, the Wellcome-MRC Cambridge Stem Cell Institute, and others have published a study that offers a new theory of aging in the journal Nature.

Somatic mutations, or alterations to the genetic code, occur in all human cells during the course of a lifetime. Aging is most likely caused by the accumulation of numerous sorts of damage to our cells over time, with one hypothesis proposing that the accumulation of somatic mutations causes cells to gradually lose functional reserve. However, it is still unknown how such slow-building molecular damage may result in the rapid decline in organ performance around the age of 70.

The Wellcome Sanger Institute, the Cambridge Stem Cell Institute, and collaborators examined the production of blood cells from the bone marrow in 10 people ranging in age from newborns to the elderly in order to better understand how the body ages.

3,579 blood stem cells had their whole genomes sequenced, allowing researchers to determine every somatic mutation present in each cell. Using this information, the team was able to create family trees of each persons blood stem cells, providing for the first time an impartial perspective of the connections between blood cells and how these ties develop over the course of a persons lifetime.

After the age of 70 years, the researchers discovered that these family trees underwent significant change. In adults under the age of 65, 20,000 to 200,000 stem cells contributed roughly equal amounts to the creation of blood cells. In contrast, blood production was exceedingly uneven in those above the age of 70.

In every elderly person investigated, a small number of enlarged stem cell clonesas few as 10 to 20contributed as much as half of the total blood output. Because of an uncommon class of somatic mutations known as driver mutations, these highly active stem cells have gradually increased in number during that persons life.

These findings led the team to propose a model in which age-associated changes in blood production come from somatic mutations causing selfish stem cells to dominate the bone marrow in the elderly. This model, with the steady introduction of driver mutations that cause the growth of functionally altered clones over decades, explains the dramatic and inevitable shift to reduced diversity of blood cell populations after the age of 70. Which clones become dominant varies from person to person, and so the model also explains the variation seen in disease risk and other characteristics in older adults. A second study, also published in Nature, explores how different individual driver mutations affect cell growth rates over time.

Dr. Emily Mitchell, Haematology Registrar at Addenbrookes Hospital, a Ph.D. student at the Wellcome Sanger Institute, and lead researcher on the study, said: Our findings show that the diversity of blood stem cells is lost in older age due to positive selection of faster-growing clones with driver mutations.

These clones outcompete the slower-growing ones. In many cases this increased fitness at the stem cell level likely comes at a cost their ability to produce functional mature blood cells is impaired, so explaining the observed age-related loss of function in the blood system.

Dr. Elisa Laurenti, Assistant Professor and Wellcome Royal Society Sir Henry Dale Fellow at the Wellcome-MRC Cambridge Stem Cell Institute at the University of Cambridge, and joint senior researcher on this study, said: Factors such as chronic inflammation, smoking, infection, and chemotherapy cause earlier growth of clones with cancer-driving mutations. We predict that these factors also bring forward the decline in blood stem cell diversity associated with aging. It is possible that there are factors that might slow this process down, too. We now have the exciting task of figuring out how these newly discovered mutations affect blood function in the elderly, so we can learn how to minimize disease risk and promote healthy aging.

Dr. Peter Campbell, Head of the Cancer, Ageing and Somatic Mutation Programme at the Wellcome Sanger Institute, and senior researcher on the study said: Weve shown, for the first time, how steadily accumulating mutations throughout life lead to a catastrophic and inevitable change in blood cell populations after the age of 70. What is super exciting about this model is that it may well apply to other organ systems too. We see these selfish clones with driver mutations expanding with age in many other tissues of the body we know this can increase cancer risk, but it could also be contributing to other functional changes associated with aging.

References: Clonal dynamics of haematopoiesis across the human lifespan by Emily Mitchell, Michael Spencer Chapman, Nicholas Williams, Kevin J. Dawson, Nicole Mende, Emily F. Calderbank, Hyunchul Jung, Thomas Mitchell, Tim H. H. Coorens, David H. Spencer, Heather Machado, Henry Lee-Six, Megan Davies, Daniel Hayler, Margarete A. Fabre, Krishnaa Mahbubani, Federico Abascal, Alex Cagan, George S. Vassiliou, Joanna Baxter, Inigo Martincorena, Michael R. Stratton, David G. Kent, Krishna Chatterjee, Kourosh Saeb Parsy, Anthony R. Green, Jyoti Nangalia, Elisa Laurenti, and Peter J. Campbell, 1 June 2022, Nature. DOI: 10.1038/s41586-022-04786-y

The longitudinal dynamics and natural history of clonal haematopoiesis by Margarete A. Fabre, Jos Guilherme de Almeida, Edoardo Fiorillo, Emily Mitchell, Aristi Damaskou, Justyna Rak, Valeria Orr, Michele Marongiu, Michael Spencer Chapman, M. S. Vijayabaskar, Joanna Baxter, Claire Hardy, Federico Abascal, Nicholas Williams, Jyoti Nangalia, Iigo Martincorena, Peter J. Campbell, Eoin F. McKinney, Francesco Cucca, Moritz Gerstung, and George S. Vassiliou, 1 June 2022, Nature. DOI: 10.1038/s41586-022-04785-z

The study was funded by Wellcome and the William B Harrison Foundation.

Excerpt from:
Scientists Unlock the Secrets of Cellular Aging: What Happens After You Turn 70? - SciTechDaily

Researchers revive abandoned technique in effort to make artificial human eggs in a test tube – STAT

In a little-noticed study published earlier this year, scientists from Oregon Health & Science University reported the birth of three mouse pups that had been created with a never-before-used recipe for reproduction. Using a common cloning technique, researchers removed the genetic material from one females eggs and replaced them with nuclear DNA from the skin cells of another. Then with a novel chemical cocktail, they nudged the eggs to lose half their new sets of chromosomes and fertilized them with mouse sperm.

In a big step toward achieving in vitro gametogenesis one of reproductive medicines more ambitious moonshots the group led by pioneering fertility researcher Shoukrat Mitalipov now intends to use the same method to make artificial human embryos in a test tube.

If successful, the research holds enormous potential for treating infertility, preventing heritable diseases, and opening up the possibility for same-sex couples to have genetically related children.

advertisement

Its one of those high-risk, high reward type of projects, said Paula Amato, an OB-GYN and infertility specialist at OHSU who collects the human eggs used in Mitalipovs experiments. We have no idea yet if it will work, but age-related fertility decline remains an intractable problem in our field, so were eternally grateful to these private funders who are filling a real need here.

Mitalipov directs the Center for Embryonic Cell and Gene Therapy at OHSU. Established in 2013, the center focuses on combining assisted reproductive technologies with genetic correction techniques, with the goal of one day preventing inherited disease.

advertisement

Related:

The groups work on in vitro gametogenesis (IVG) in human cells is being made possible by an award from Open Philanthropy a grant-making organization primarily funded by Facebook co-founder Dustin Moskovitz and his wife Cari Tuna which will supply the researchers with $4 million over the next three years. The infusion of funds and the involvement of a scientist as storied as Mitalipov makes the ethical and legal questions surrounding mass egg and sperm production more urgent, experts told STAT.

In the U.S., there are no federal laws that prohibit this type of IVG work. However, Congress has barred any research that creates, destroys, or knowingly harms human embryos from receiving federal funding. At the state level, laws governing human embryo research vary widely with 11 states banning it entirely, five states expressly permitting it, and a lot of gray areas in between.

For IVG to move from the research lab to a fertility clinic would require permission from the Food and Drug Administration. Its still unclear if thats something the agency would be able to consider a spending bill rider currently prevents the FDA from receiving any requests to pursue clinical trials involving starting pregnancies with embryos that have been genetically manipulated. In 2019, Congress considered modifying the ban, following a push from scientists and advocates of mitochondrial replacement therapy, also known as three-person IVF, but ultimately renewed it. Mitochondrial replacement therapy is a procedure that combines genetic material from an egg and sperm with mitochondria from a female donor.

Somatic cell nuclear transfer for IVG could fall under the same provision, if the somatic DNA and the egg came from different people. But if they came from the same person, that might represent a loophole.

Related:

Some bioethicists worry that the easy availability of IVG could usher in a new era of eugenics, scenarios where prospective parents could create large numbers of embryos and use genetic tools to select the best one. IVG also raises the specter of nonconsensual parenthood something most state laws are currently ill-equipped to handle.

Should this become clinically available, there will be legitimate questions about whose cells can be used and under what conditions that will need regulatory answers, said Hank Greely, director of the Stanford Center for Law and Bioscience, whose book, The End of Sex, examines the future of in vitro gametogenesis. Will that happen? We dont know. But Mitalipov has certainly proven himself a bold and creative scientist, and from my perspective, having his group join the effort to help people who want to have genetic babies but cant is a good thing, provided they can do it safely and effectively.

Mitalipovs lab has long been an incubator for envelope-pushing science. In 2009, he and his colleagues figured out a way to swap out glitchy mitochondrial DNA for healthy versions in the egg cells of monkeys a groundbreaking advance that paved the way for mitochondrial replacement therapy in humans. In 2013, they created lines of embryonic stem cells from cloned human embryos for the first time. A few years later, they became the first team in the U.S. to attempt to correct a genetic mutation in viable human embryos using CRISPR.

But until recently, in vitro gametogenesis, or IVG, wasnt on his to-do list.

Gametes are the cells capable of giving rise to future generations: sperm and eggs. The idea behind IVG is to produce those kinds of cells in test tubes, rather than inside a developing animals body.

In recent years, scientists have made headlines producing artificial gametes from induced pluripotent stem cells. But Mitalipovs group plans to revive a much older technology, which saw some early success in IVG before being abandoned: somatic cell nuclear transfer.

Somatic cell nuclear transfer was pioneered by researchers at the Roslin Institute in Scotland. After they succeeded in using the technique to clone the first mammal a sheep named Dolly scientists realized it might be used to generate artificial gametes, if they could overcome a few additional hurdles.

In cloning, the emptied egg receives a full set of chromosomes from the somatic cell donor and is stimulated in the lab to make it start dividing. Any offspring that result will be genetically identical to that somatic cell.

The procedure for making an artificial oocyte is technically similar to cloning, but would generate unique individuals after fertilization with sperm. However, in order for any resulting embryos to have the right number of chromosomes, the donor DNA has to be cut in half, a process known as haploidization. Oocytes are equipped with the machinery to make that adjustment, if the somatic DNA is introduced at the right phase of their cell cycle.

In 2000, four years after Dolly was born, researchers in Spain generated the first human artificial oocytes using this method. They fertilized three of them, and froze the resulting embryos at the two-cell stage. The plan was to transfer the frozen embryos to the uterus of a woman who had been unable to conceive, and consented to having her somatic DNA slipped into donor eggs as a last-ditch attempt to have genetically related children with her husband.

Related:

But when the same protocol was tested in mice where its effects could be examined more closely the chromosomes didnt separate as intended. Shortly thereafter, somatic cell nuclear transfer for human reproduction was banned in many countries, including Spain.

The IVG field moved on, buoyed by the discovery a few years later of a method for taking any kind of cell and rewinding its developmental clock to a more primitive state. With the right chemical cues, a team of Japanese scientists nudged these pluripotent stem cells to produce functional gametes in mice; first sperm in 2011, then eggs, five years later. But they struggled to generate similar results in humans.

In 2018, the group succeeded for the first time in making immature human eggs from scratch. But the process wasnt very efficient and it involved incubating the human stem cells in mini-ovaries theyd created in the lab from mouse embryonic cells a resource-intensive process not exactly suited to mass manufacturing.

So when a post-doc at OHSU named Eunju Kang proposed revisiting the idea of somatic cell nuclear transfer for IVG, Mitalipov was initially skeptical. But data from her initial mouse experiments proved persuasive. Mitalipov threw his support behind the project, and teamed up with a group at Weill Cornell Medicine in New York, including reproductive endocrinologist Gianpiero Palermo, who had successfully generated artificial human oocytes using cloning technology back in 2002. They published the results of their mice experiments in Nature Communications Biology in January.

Related:

The OHSU team is now adapting those methods to see if they can generate artificial human eggs with properly separated chromosomes. If successful, they plan to then fertilize those eggs with sperm and grow the resulting embryos in the lab for five or six days to see if they develop normally.

They are betting that this method, while older, will prove better than the induced pluripotent stem cell technologies currently being advanced by artificial egg-making start-up outfits like Conception, Ivy Natal and Gameto.

That approach requires the cells to be cultured for months rather than days, which can lead to epigenetic programming errors and chromosomal instability. Mitalipov also believes that starting with natural eggs will make it easier to strip the donor DNA of its cellular memory and return it to the primitive state known as totipotency a critical step in enabling the embryo to eventually develop all the specialized tissues that make up a human body.

Science Writer

Megan Molteni is a science writer for STAT, covering genomic medicine, neuroscience, and reproductive tech.

This name will appear with your comment

Link:
Researchers revive abandoned technique in effort to make artificial human eggs in a test tube - STAT

Global Stem Cells Group Expands Its Stem Cell Therapy and Regenerative Medicine Centers to Indonesia – GlobeNewswire

LAS VEGAS, NV, Aug. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology company specializing in Biotech and Numismatics, is pleased to announce additional global expansion by opening stem cell therapy and regenerative medicine facilities in Indonesia. The new facilities emphasize Global Stem Cells Group's objective of introducing its therapies and technology to meet market demands in populous parts of the world.

In partnership with the Dr. Yanti Aesthetic Clinics, which currently has 6 branches across Indonesia, this latest GSCG expansion will promote high standards of service in regenerative medicine across the country. As part of this effort, through GSCG the International Society for Stem Cells Applications (ISSCA) has granted Dr. Yanti Aesthetic Clinics membership and use of its brand, products, therapies, and training on how to apply stem cell therapies.

This new partnership seeks to expand the Global Stem Cells Group (GSCG) brand and create centers of excellence in cell therapy to meet the high demand within the vast Asian markets, said David Christensen, CEO of MSSV. GSCG is rapidly expanding its global operations as it seeks to become a significant player in the lucrative regenerative medicine industry. To achieve our expansion plans, our organization is partnering with healthcare providers specializing in regenerative medicine with at least five years of experience in the healthcare sector.

Video: https://youtu.be/T2CFjsps9qk

The vision behind the effort.

The Indonesia addition is the latest part of an expanding medical network of partners, and it will formalize and strengthen ties, establishing a global center of excellence to guarantee that we effectively use the underlying basic stem cell technology for medical conditions, where traditional therapeutic approaches seem to have failed. This is consistent with GSCG's overall strategy for developing regenerative medicine through data-driven studies, disease modeling, and cell-based therapeutics.

The Dr. Yanti Aesthetic Clinic is a key partnership because it provides the organizational and physical infrastructure needed to disseminate need-based stem cell locally. And Global Stem Cells Group's outstanding cell and stem cell biology and disease pathophysiology give an edge to patients for which they are prescribed.

The opening in Indonesia also presents the perfect opportunity to translate breakthrough therapies from basic discoveries to useful products by drawing upon the skills and local knowledge promoted within Dr. Yanti Aesthetic Clinics.

GSCG group managing director, Benito Novas, provided a clear description of the new strategic direction and objectives. "Our goal is to make regenerative medicine benefits a reality for both doctors and patients all around the world. We recently launched a very similar effort in Pakistan. Additional announcements are planned in the near future as we attempt to expand our presence." Meso Numismatics and Global Stem Cells Group Expand its Global Footprint

The current market outlook.

Stem cell therapy is striving to become an increasingly effective clinical solution to treat conditions that traditional or mainstream medicine offers only within palliative care and pain management. Patients all over the world are searching for a natural regenerative alternative without the potential risks and side effects sometimes associated with mainstream pharmaceuticals. With the opening of each new treatment center in populous regions such as Indonesia, GSCG is working to help stem cell therapy and regenerative medicine to eventually move from alternative and elective procedures to mainstream protocols.

This new clinic effort will play a significant role in the development of regenerative medicine in Indonesia and indeed the rest of the world by adding yet another opportunity for continuous improvement through research and development, Christensen continued. By adding busy clinics in population centers, we plan to consistently generate high volumes of reliable clinical data to assist us with the development and refinement of even more medicines and treatments.

About Dr. Yanti Aesthetic Clinics

Dr. Yanti Aesthetic Clinics is a premier cosmetic and aesthetics clinic based in Kelapa Gading, Jakarta Utara. Since its inception in 2004 in Surabaya by Dr. Khoe Yanti Khusmiran, the clinic has expanded to over 6 branches throughout Indonesia. Dr. Yanti clinics provide a range of skin and body enhancement treatments through minimally invasive and non-invasive procedures the expertise of which are a natural fit for the addition of a variety of stem cell therapies.

"Indonesians have a growing need for the latest medical technology that is reliable, potent, has reduced side effects, and leverages the bodys own healing biochemistry to resolve injury and aging, said Dr. Yanti. We are honored to be a part of GSCG, which has a proven 10-year track record in the market with a strong and growing international reputation. This new partnership is expected to create a wide variety of custom treatment options we can offer our patients and treat injury and illness in ways we could not before.

The newly formed partnership will deliver revolutionary medicines through Dr. Yanti clinics to assist patients in avoiding permanent harm and live a healthier life, while changing the paradigm from asymptomatic treatments to cures that may improve and restore quality of life.

More about Global Stem Cells Group

GSCG delivers leadership in regenerative medicine research, patient applications, and training through our strategic global networks. We endeavor to enable physicians to treat otherwise incurable diseases using stem cell therapy and to improve the quality of life and care across the world.

For this reason, GSCG works with innovative, next-generation therapy providers like Dr. Yanti Aesthetic Clinics to give access to one-of-a-kind holistic and safe treatment options.

More information regarding this transaction and the Global Stem Cells Group may be found at GSCG.

This press release should be read in conjunction with all other filings on http://www.sec.gov

For more information on Global Stem Cells Group please visit: http://www.stemcellsgroup.com

About Meso Numismatics: Meso Numismatics, Corp is an emerging Biotechnology and numismatic technology company. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world.

Meso has now added Biotechnology to its portfolio and will continue to grow the company in this new direction. With the Company's breadth of business experience and technology team, the Company will continue to help companies grow.

Forward-Looking Statements

Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words plan, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Meso Numismatics, Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Meso Numismatics, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

For further information, please contact: investor.relations@mssvinc.com Telephone: (800) 956-3935

Read more:
Global Stem Cells Group Expands Its Stem Cell Therapy and Regenerative Medicine Centers to Indonesia - GlobeNewswire

Cell Therapy Bioprocessing Market is anticipated to accumulate USD 30052.6 million by 2028, says The Insight Partners – Digital Journal

According to The Insight Partners research, the cell therapy bioprocessing market was assessed at US$ 11,192.50 million in 2020 and is projected to be worth US$ 30,052.61 million by 2028, growing at a 13.5% CAGR between 2021 and 2028. Increasing investments for cell and gene therapy manufacturing and growing approvals for cell therapies are expected to be the prime drivers for the cell therapy bioprocessing market.

Cell and gene therapy is still in an early stage of development in the biotechnology sector. Despite being a niche domain of the biotechnology sector, cell and gene therapy has paved investments by contract development and manufacturing organizations (CDMO)/contract manufacturing organizations (CMO). Companies are investing in enhancing their manufacturing capabilities and offering world-class therapies to treat chronic conditions. In February 2020, Catalent, Inc. and MaSTherCell Global, Inc. signed an agreement in which Catalent, Inc. agreed to acquire MaSTherCell Global, Inc. for an amount of US$ 135 million. According to the Alliance for Regenerative Medicine (ARM), investments in cell and gene therapy doubled in 2020 compared to 2019 and were considerably higher than in 2018. Thus, owing to the heavy investments, the market is expected to flourish in the coming years.

Get Sample PDF Copy of Cell Therapy Bioprocessing Market Size, Share, Growth- COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.theinsightpartners.com/sample/TIPRE00021550/

Leading players profiled in the cell therapy bioprocessing market report are Fresenius Kabi AG, Asahi Kasei Corporation, Sartorius AG, Merck KGaA, Thermo Fisher Scientific Inc, Corning Incorporated, Cytiva (GE Healthcare), Lonza, Repligen, and Catalent Inc.

Based on end user, the cell therapy bioprocessing market is segmented into hospitals and clinics, diagnostic centers, regenerative medicine centers, and academic and research institutes. The academic and research institute segment held the largest share of the market in 2020. The segment is estimated to register the highest CAGR of 14.1% in the market during the forecast period. It was valued at US$ 4,331.72 million in 2020 and is projected to reach US$ 12,141.53 million by 2028.

From the regional frame of reference, North America held a significant share in the cell therapy bioprocessing market in 2020. The regional market was assessed at US$ 5,031.03 million in 2020 and is slated to amass US$ 13,700.98 million by 2028, growing at a CAGR 13.7% during the forecast period. Meanwhile, APAC is predicted to register a stellar growth rate of 14.0% over the analysis period to garner US$ 5,872.28 million by 2028.

Avail Lucrative DISCOUNTS on Cell Therapy Bioprocessing Market Research Study: https://www.theinsightpartners.com/discount/TIPRE00021550/

Cell therapy involves the production of cartilage repair products, tissue-engineered skin, personalized medicines, and cellular immunotherapy to treat chronic diseases. The increasing need to treat chronic diseases has pushed the research and development activities resulting in growing cell therapy production and product approvals. Growing product developments have resulted in various product approvals that reflect the increase in cell therapies. Therefore, it is expected that the growing approvals for cell therapies are enormously increasing the cell therapy bioprocessing, which, in turn, is likely to drive the markets growth over the coming years.

On the other hand, cell therapy bioprocessing challenges hinder cell therapy bioprocessing augmentation.

Based on technology, the cell therapy bioprocessing market is divided into a bioreactor, lyophilization, electrospinning, control-flow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. Of these, the bioreactor segment held 31.47% of the market share in 2020. The segment was assessed at US$ 3,521.94 million in 2020 and is projected to reach US$ 9,977.79 million by 2028, growing at a 14.2% CAGR during the forecast period.

As per cell type, the market is divided into stem cells, immune cells, human embryonic stem cells, pluripotent stem cells, and hematopoietic stem cells. Of these, the stem cell segment registered 48.53% of the market share in 2020. The segment was evaluated at US$ 5,431.23 million in 2020 and is slated to amass US$ 15,171.69 million by 2028, expanding at a 14% CAGR between 2021 and 2028.

Moving on to indication, the cell therapy bioprocessing market is divided into cardiovascular disease (CVD), oncology, wound healing, orthopedic, and others. Among these, the oncology segment accounted for 37.11% of the market share in 2020. The segment was evaluated at US$ 4,154.07 million in 2020 and is slated to garner US$ 11,530.16 million by 2028, augmenting at a 13.9% CAGR between 2021 and 2028.

Directly Purchase Premium Copy of cell therapy bioprocessing Market Growth Report at: https://www.theinsightpartners.com/buy/TIPRE00021550/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: [emailprotected]

Phone: +1-646-491-9876

More:
Cell Therapy Bioprocessing Market is anticipated to accumulate USD 30052.6 million by 2028, says The Insight Partners - Digital Journal

Uncovering New Approaches to a Common Inherited Heart Disorder – Yale School of Medicine

Research led by Muhammad Riaz, PhD, Jinkyu Park, PhD, and Lorenzo Sewanan, MD, PhD, from the Qyang and Campbell laboratories at Yale, provides a mechanism to identify abnormalities linked with a hereditary cardiac condition, hypertrophic cardiomyopathy (HCM), in which walls of the left ventricle become abnormally thick and often stiff. The findings appear in the journal Circulation.

Patients with familial HCM have an increased risk of sudden death, heart failure, and arrhythmias. HCM is the most common inherited cardiac disease, affecting one in 500 people. The disease is thought to be caused by mutations that regulate cardiac muscle contraction, compromising the hearts ability to pump blood. However, the mechanisms behind the disease are poorly understood.

For this multi-model study, the researchers used stem cell approaches to understand the mechanisms that drive inherited HCM. The technology, induced pluripotent stem cells (iPSCs), can accelerate insights into the genetic causes of disease and the development of new treatments using the patients own cells.

This is a humbling experience that a patients disease phenotypes teach researchers fundamental basic knowledge that sets the stage for innovative new therapies. Furthermore, our research has established a great model to assist many physicians at Yale School of Medicine and Yale New Haven Hospital to unravel mechanistic insights into disease progression using the patients own iPSCs and engineered tissues, said Yibing Qyang, PhD, associate professor of medicine (cardiology) and of pathology.

We wanted to understand the disease mechanism and find a new therapeutic strategy, Park said.

The concept originated with an 18-month-old patient who suffered from familial HCM. Through a collaboration with Daniel Jacoby, MD, adjunct associate professor of cardiovascular medicine and an expert on HCM, who provided medical care for this patient, Park and the team used stem cell technologies to address a fundamental question, the disease mechanisms behind HCM. They collected 10 cc of the patients blood and introduced stem cell factors into the blood cells to generate self-renewable iPSCs. By applying cardiac knowledge, they coaxed iPSCs into patients own cardiomyocytes (heart cells) for cardiac disease studies. We discovered a general mechanism which explains the disease progression, said Park.

Next, they engineered heart tissues that resembled the early-onset disease scenario of the young patient. The disease was a severe presentation at the age of 18 months, which suggested that the disease started at the fetal/neonatal stage.

The next phase of the study was to recreate a 3-D model that was used to mimic the progression of the disease, including mechanical properties such as contraction and force production of that muscle, to understand how much force is compromised if the mutation is present. This was performed in collaboration with Stuart Campbell, PhD, and Sewanan from Yales Department of Biomedical Engineering. Coupled with computational modeling for muscle contraction, the authors developed robust systems that allowed them to examine the biomechanical properties of the tissue at three-dimensional levels.

Finally, using advanced gene editing technologies, the research team modified these mutations. They discovered that after the mutations were corrected, the disease was reversed. These insights about sarcomeric protein mutations could lead to novel therapeutics for HCM and other diseases. The interaction between mutations could also suggest that the same biomechanical mechanism exists in other conditions such as ischemic heart disease.

We can apply these findings to cardiac conditions associated with hypertension, diabetes, or aging, said Riaz.

One of the fundamental challenges was that we needed to generate iPSCs from the patients family, Riaz added. Using this technology, Park was able to recreate primary cells from the cells of a patient with HCM, a process which takes over a month. Riaz and Park used stem cells to identify the vital role of pathological tissue remodeling, which is caused by sarcomeric hypertrophic cardiomyopathy mutations.

We are hopeful that our findings will be replicated in the scientific community, said Riaz. This is an example of bed to bench research, where scientists extract materials from clinics and conduct the experiment in the laboratory and then discover new methods to treat patients.

The authors also noted that RNA sequencing could be used as a guide to characterize the disease at a molecular level. Scientists may be able to identify more targeted drugs by examining the biomechanical properties of the tissue. We can now screen multiple drugs to see whether any of those drugs are able to rescue the phenotype, they said.

Riaz, now an associate research scientist in the Qyang lab, began as a cancer researcher. He earned a PhD from the Erasmus University Medical Center, based in Rotterdam, Netherlands. He later studied genetic disorders in skeletal muscle disease before joining the lab in 2017.

Park, also from the Qyang lab, graduated from Seoul National University, South Korea in 2013. He completed postdoctoral research at the University of Missouri where he focused on vascular biology and emerging areas in stem cell technology.

Yales Lorenzo R. Sewanan, MD, PhD, Yongming Ren, PhD, Jonas Schwan, PhD, Subhash K. Das, PhD, Pawel T. Pomianowski, MD, Yan Huang, PhD, Matthew W. Ellis, BS, Jiesi Luo, PhD, Caihong Qiu, PhD, George Tellides, MD, PhD, John Hwa, MD, PhD, Lawrence H. Young, MD, Daniel L. Jacoby, MD, and Yibing Qyang contributed to this study. Additional coauthors are Indiana Universitys Juli Liu, PhD and Lei Yang, PhD; Columbia Universitys Loujin Song, PhD, Masayuki Yazawa, PhD, and I-Ping Chen, DDS, PhD.

Funding for the research came, in part, from the National Institutes of Health, Department of Defense, and the American Heart Association.

Link:
Uncovering New Approaches to a Common Inherited Heart Disorder - Yale School of Medicine

NK Cell Therapy and Stem Cell Therapy Market Investment Analysis Shanghaiist – Shanghaiist

Published By Marketreports.info

NK Cell Therapy and Stem Cell Therapy Market research report including customer preference analysis, market dynamics (drivers, restraints, opportunities) segmentations like Types, Applications, Regions (United States, Europe, China, Japan, India, Southeast Asia, Latin America, Middle East and Africa) and Manufactures.

Final Report will add the analysis of the impact of COVID-19 on this industry.

Global NK Cell Therapy and Stem Cell Therapy Market 2022-2030 research report focuses on the product overview, scope, market upstream and downstream analysis, players profiles, market landscape by player, sales, revenue, price trend, market forecast, market drivers analysis, restraints and challenges, opportunities analysis, size, segmentations (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19 containing 150 numbers of pages, tables, figures and charts.

Get a Sample PDF of the Report marketreports.info/sample/81636/NK-Cell-Therapy-and-Stem-Cell-Therapy

Market Analysis and Insights: Global NK Cell Therapy and Stem Cell Therapy Market

The NK Cell Therapy and Stem Cell Therapy market has witnessed a growth from xx USD million to xx USD million from 2014 to 2022. With a CAGR of xx%, this market is estimated to reach xx USD million in 2030.

The major players covered in the NK Cell Therapy and Stem Cell Therapy market report are: Chipscreen Biosciences, Affimed NV, Altor BioScience Corporation, Innate Pharma SA, Takeda Pharmaceutical, Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed

Get a Sample Copy of the NK Cell Therapy and Stem Cell Therapy Market Report 2022 : marketreports.info/sample/81636/NK-Cell-Therapy-and-Stem-Cell-Therapy

By Type NK Cell Therapy Stem Cell Therapy

By Application Hospital & clinics Regenerative medicine centers Diagnostic centers Research institutes Others

Major Regions or countries covered in this report:

United States Europe China Japan India Southeast Asia Latin America Middle East and Africa Others Years considered for this report:

Historical Years: 2014-2021 Base Year: 2021 Estimated Year: 2022 Forecast Period: 2022-2030

The Study Objectives of this report are:

To analysis the worldwide NK Cell Therapy and Stem Cell Therapy market size by product types, applications and regions. To comprehend the design of NK Cell Therapy and Stem Cell Therapy market by recognizing its different sub-fragments. To study NK Cell Therapy and Stem Cell Therapy by individual manufactures growth, future trends. To study Product Overview and Scope of NK Cell Therapy and Stem Cell Therapy market segment, Revenue Sales Status and Outlook To study Manufacturing Cost Structure of NK Cell Therapy and Stem Cell Therapy market To understand market Upstream and Downstream analysis To understand Market Competitive Situation and Trends To understand market Drivers, Restraints, Opportunities, Challenges faced by NK Cell Therapy and Stem Cell Therapy market To analysis new product and new technology release Analysis of Industry Development Trends under COVID-19 Outbreak

Purchase this Report marketreports.info/checkout?buynow=81636/NK-Cell-Therapy-and-Stem-Cell-Therapy

About Us:

Marketreports.info is the Credible Source for Gaining the Market Reports that will provide you with the Lead Your Business Needs. The market is changing rapidly with the ongoing expansion of the industry. Advancement in technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies a head start in planning and an edge over the competitors.

Contact Us

Market Reports

Phone (UK): +44 141 628 5998

Email: sales@marketreports.info

Web: https://www.marketreports.info

Go here to see the original:
NK Cell Therapy and Stem Cell Therapy Market Investment Analysis Shanghaiist - Shanghaiist

Buffalo center fuels research that can save your life from heart disease and stroke – Buffalo News

Dr. Jennifer Lang splits most of her work life treating patients at Gates Vascular Institute and conducting research in her lab several floors up in the same building.

UB medical physics students Simon Wu and Emily Vanderbelt work with flow-through 3D-printed aneurysm models using X-rays in the Canon Stroke & Vascular Research Center, part of the University at BuffaloClinical and Translational Research Center on the Buffalo Niagara Medical Campus.

The arrangement suits her well as she continues promising research to learn if a stem cell-derived treatment can repair damaged heart tissue.

Lang, a cardiologist, and her University at Buffalo team, face a dilemma: The immune system revs into high gear when the heart suffers a serious setback, limiting the power of stem cells to heal.

The daunting task seems more surmountable these days because she works in a building filled with researchers of all stripes.

I do collaborations with groups that I otherwise wouldn't have. Its led to some really new, interesting results, said Lang, assistant professor in the UB Jacobs School of Medicine and Biomedical Sciences who practices with UBMD Internal Medicine and at the Buffalo VA Medical Center.

This day, a surgical team worked seamlessly to monitor her vital signs and feather a medical device through a catheter into the left side of her damaged heart. The procedure slowed her heartrate so her organs could take a couple of days to re-collect themselves and give her a fighting chance to recover.

UB-fueled research unfolds on floors five through eight of the building at 875 Ellicott St., alongside Buffalo General Medical Center.

Ten years ago, the university invested $118 million into its Clinical and Translational Research Center, and about $25 million for equipment came from industry partners who wanted to join forces with physicians, engineers and others in the science fields.

The center became the first major pieceof the UB medical school to move onto the downtown Buffalo Niagara Medical Campus, followed in late 2017 by the $375 million Jacobs School teaching and research complex, around the corner at Main and High streets.

Both foster translational medicine, which combines disciplines, resources and techniques to move benchtop research to the patient bedside, eventually strengthening community health.

Langs work symbolizes the approach.

The Buffalo native can see her high school alma mater, City Honors, from her workplace. She went to Cornell University as an undergraduate and returned to Buffalo to go to medical school. Buoyed by fellow UB students, faculty and mentors, she chose to stay in the city for her internal medicine residency and cardiology fellowship.

Lang did her classroom work and research on the UB South Campus and most of her clinical work 8 miles away, on the downtown Medical Campus.

Stairs and elevators are the only things that separate her from most of her collaborators and patients today.

I moved into this building when it opened 10 years ago, she said. At the time, I was completing my cardiology fellowship. There was a physical divide, so I was thrilled with the new arrangement. Things can happen in parallel now.

Dr. Timothy Murphy, left, director of theUB Clinical and Translational Research Center in Buffalo, works with research technician Charmaine Kirkham in their lab, which focuses on potential treatments forchronic obstructive pulmonary disease (COPD).

That was the plan, said Dr. Timothy Murphy, director of the UB Clinical and Translational Research Center.

Clinical research and health care have become more and more seamlessly integrated, he said. The building contributed to that.

Murphy, another regional native, was among those who shared and helped carry out the vision of Gates Vascular Institute founder Dr. L. Nelson Nick Hopkins III, who chaired the UB Department of Neurosurgery from 1989 to 2013 and wanted to create a more innovative vascular center.

Murphy moved his lab in 2006 from the VA Medical Center near South Campus to the UB Center for Bioinformatics and Life Sciences on the Medical Campus, so he could be involved in the design of the UB research center, on floors above Gates Vascular, as well as at the Jacobs School particularly its labs.

They always talked about physicians and researchers bumping into each other, talking to each other, and having graduate students and postdocs and technicians talk to each other, Murphy said. Having done it now for all these years, I see it really does work.

He and his research team continue a 20-year study on the bacterial infection that causes COPD in hopes it will help lead to vaccines that prevent the infection and new treatments to clear the bacteria from the lower airway.

As senior associate dean forclinical and translational researchat the Jacobs School, he is also the point person for coordinating UB-related clinical trials and encouraging collisions between health care researchers on the Medical Campus and around the world.

There were 70 such trials on the Medical Campus in 2015, when the building where he works was in its infancy. Today, there are more than 200.

"Things can happen in parallel now," says Dr. Jennifer Lang, a cardiologist, researcher and University at Buffalo assistant professor who splits her research and clinical time in the same building on the Buffalo Niagara Medical Campus.

Labs focused on obstetric and gynecological advances and keys to healthy aging occupy space near his seventh-floor lab.

The Clinical and Translational Research Center was established in 2012. UB added a biobank in 2019 to store medical specimens for ongoing clinical studies.

Its collaborative framework helped UB land a $15 million Clinical and Translational Science Awardin 2015 from the National Institutes of Health (NIH) to encourage research efforts across university departments and specialties to boost innovation, speed development of medical treatments, and reduce health disparities in poor, rural and minority communities.

The five-year grant was renewed in 2020 with nearly $22 million more, encouraging Buffalo-based researchers to work with others who got awards, including researchers with Harvard, Johns Hopkins, Stanford and Yale universities.

A printer creates a 3D model, slice by slice, at the Canon Stroke & Vascular Research Center in the University at Buffalo Clinical and Translational Research Center. Lab researchers experiment with different mixtures of six polymers to make the most malleable and useful models for medical research.

Throughout the building, the goal is to improve medical devices and treatments that make an impact in the clinics and catheter suites in the Gates Vascular Institute on the floors below the research center and provide data and education that informs others, including patients.

The eighth-floor Canon Stroke & Vascular Research Center, which tops the UB research center, is a case in point.

Ciprian Chip Ionita, its director, came to UB from Romania in 1999 and worked his first dozen years on the South Campus.

We were the first ones to move in, said Ionita, assistant professor of biomedical engineering and member of the medical school's Department of Neurosurgery.

The lab was designed to help innovate and improve medical devices and neurovascular procedures.

Part of its work involves using MRIs, CT scans and other radiological images of Gates Vascular patients to create 3D-printed models of the circulatory system and heart.

3D printing created this replica of part of a patient's spinal column at the Canon Stroke & Vascular Research Center. Researchers there push the boundaries until their findings are refined to the point where they can be applied to model-making on two highly calibrated 3D printers in the Jacobs Institute downstairs from the lab that meet FDA standards. We fail up here about 90% of the time, says Ciprian Chip Ionita, lab director. They fail maybe 1%, so were testing everything that's possible.

Medical school and other lab researchers use the models produced here to better understand how anatomy and disease of former and current patients led to poor health and, in some cases, poor surgical outcomes.

Gates Vascular surgeons also can use 3D models that replicate the anatomy of patients awaiting surgery to practice feathering catheters and medical devices through bends, nooks and crannies of the blood vessels, and deploy medical devices in spines and the circulatory system as they maneuver past muscles, bones, blockages and other obstructions that might come into play.

During practice interventions, we analyze everything, Ionita said, because we can go into these models with sensors to measure blood flow, blood pressure and more.

You can create a model that says, Here's somebody who has a carotid artery that's 50% (blocked) and he's 50 years old, Ionita said. Or we can say, 'Here is a young person in their 20s, and is fully compliant, no stenosis or whatever.' And those mechanical properties are translated by the printer.

Even cadaver donors cant do that.

The goal is to lower the rate of complications and be successful in one shot during a procedure, said Ionita, who supervises up to 10 graduate biomedical engineering students, and roughly 20 undergraduate, graduate and medical school students.

Those who pay close attention to 3D models and other medical research based on data from patients treated in the building include Dr. Elad Levy, co-director of the Gates Vascular Stroke Center; Dr. Adnan Siddiqui, director of neurological and stroke services at Kaleida Health; and Dr. Vijay Iyer, medical director of cardiology and the Structural Heart Program at Kaleida. All three have ties to UB.

Even here, Ionita said, physician-scientists and other researchers see the damage that smoking, high blood pressure and living in ZIP codes where poverty is rampant can create complications that lead to worse health and surgical outcomes.

Eric Wozniak, a senior research and development technician in the Idea to Reality lab at the Jacobs Institute, uses a microscope as he works to improve catheter technology.

Doctors and staff improve treatment protocols and surgical prowess with help from those who work on the top half of the building for UB and the Jacobs Institute. The latter is named for Dr. Lawrence D. Jacobs, a Buffalo neurosurgeon whose research led to the first treatments for multiple sclerosis.

Four years after Jacobs died in 2001, his brother Jeremy, chair of the Delaware North Cos. and the UB Council, approached the university about creating a lasting memorial for the respected physician. He later signed on to the concept of creating a multidisciplinary vascular center, starting with a $10 million donation for the institute that bears the family name.

The institute includes an atrium, caf and glass-walled spaces that overlook procedure rooms on the floor below. It has 50 employees, including more than 30 biomedical and electrical engineers, who seek company-sponsored research funding, help collect data and make prototypes for clinical trials, and work with researchers to publish their work in medical journals.

In 2016, the institute was designated a 3D Printing Center of Excellence in Health Care by Israeli-based Stratasys Ltd., a leading 3D printing-maker. In early 2018, it created a proof-of-concept Idea to Reality Center, known as i2R, to further improve medical devices and surgical techniques in the vascular space.

This is our secret sauce lab, said Siddiqui, Jacobs Institute CEO. There's nothing we do downstairs that we could not do better.

This is a device designed and built in the Idea 2 Reality lab at the Jacobs Institute in Buffalo. The lab improves medical devices and technology used in vascular procedures and treatments.

Dr. Carlos Pena, who ran the FDA Neurologic Devices Division for 15 years, joined the institute staff last year to improve the chances technology conceived and designed with help from the institute gets to market.

Every company wants to talk to him, Siddiqui said. He tells them what testing needs to be done. Some of that gets done in-house. A lot of it goes to the university or, when they have a clinical trial, that gets done downstairs so the entire ecosystem is functioning, I think better than Nick Hopkins ever imagined.

Lang, the cardiologist, doesnt miss her former workday commutes. She loves the design and location of the building that sets the standard for vascular care.

Most of her days mix benchtop research in her lab and patient visits and procedures on the floors below. When there is time, she can visit her husband, Fraser Sim, neuroscience director and associate professor at the medical school.

Because we're in such close proximity to the Jacobs School now, we're also really able to engage the medical students earlier in their careers and encourage more research, Lang said. And because we're so close to the hospital, we're able to involve medical residents and fellows in our research projects much more than ever before.

University at Buffalo medical school postdoctoral research associateToubaTarvirdizadeh focuses on cardiac research in the lab of Dr. Jennifer Lang at the UB Clinical and Translational Research Center in Buffalo.

She has spent a decade trying to find better ways for a stem cell derivative that can withstand an immune response and rejuvenate heart tissue without major complications, a result that could help patients recover from a heart attack and lessen the strain of heart failure.

Four years ago, Lang and her doctoral student researcher, Kyle Mentkowski, discovered a way that lowered the immune response in mice that received the derivative.

Mentkowski, now a post-doctorate researcher at Harvard-affiliated Massachusetts General Hospital, was talking with another group of student researchers in the building when they thought it might be a good idea to bring Dr. Jessica Reynolds, an immunologist and UB medical school associate professor, into the research.

The collaboration created robust, reproducible results in mice models, Lang said, and the start of testing in human immune cells she and her colleagues hope can benefit patients within the next decade.

Collaborators now regularly get together to chat at the Jacobs Institute.

The NIH seems very interested in this as a potential clinical therapy, Lang said, but the field as a whole is still in the beginning stages of understanding where we need to go next.

Dr. Aaron Hoffman, left, University at Buffalo medical school associate professor of surgery, and Dr. Kenneth Snyder, UB associate professor of neurosurgery, chat during a break in the Jacobs Institute atrium.

UB researchers have shared some of their findings with researchers making similar inroads elsewhere, she said, and the work spawned other collaborations with Reynolds, her research team and scientists in the UB Department of Biomedical Engineering.

This type of unplanned interaction is not a unique occurrence in this building, Lang said. Our story is just one of many.

The smart way to start your day. We sift through all the news to give you a concise, informative look at the top headlines and must-read stories every weekday.

More:
Buffalo center fuels research that can save your life from heart disease and stroke - Buffalo News

Cartilage Repair/ Cartilage Regeneration Market 2022 Size, Competitive Landscape and Key Regions 2030 This Is Ardee – This Is Ardee

Global Cartilage Repair/ Cartilage Regeneration Market Size study, By Treatment Modality (Cell-based {Chondrocyte Transplantation, Stem Cells, Growth Factors}. Non-cell-based {Tissue Scaffolds, Cell-free Composites}), By Application (Hyaline Cartilage, Fibrocartilage), By Application Site (Knee, Hip, Ankle and Foot, Other Application Sites, By End User (Hospitals, Ambulatory Surgery Centers and Clinics), and Regional Forecasts 2022-2028

Global Cartilage Repair/ Cartilage Regeneration Market is valued approximately USD 787 Million in 2021 and is anticipated to grow with a healthy growth rate of more than 15.30% over the forecast period 2022-2028.

Download Free Sample of This Strategic Report :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5129

Cartilage repair or cartilage regeneration is a treatment for the joint that are healthy but have damaged cartilage due to the injury-causing impaired function and pain. Articular cartilage injuries happen because of the obliteration of the cartilage such as traumatic injury, direct blow, and progressive degeneration. The growing incidence of bone and joint disorders, such as Osteoarthritis (OA) or arthritis, increasing obese and geriatric population, availability of research funding and investments, coupled with the technological development and advancements of innovative treatment approaches are the chief factors that may surge the market demand around the world. For instance, according to the Centers for Disease Control and Prevention (CDC), there were nearly 64 million US adults have several varieties of arthritis, a figure that is anticipated to rise 78 million by the year 2040. Also, it is expected to be above 100 types of arthritis, osteoarthritis (OA) is the most common type of arthritis, which is affecting 32.5 million US adults. Thereby, the rising prevalence of bone and joint disorders will propel the market demand in the impending years. However, the high cost of cartilage repair surgeries and several limitations of cartilage-based stem cell products impedes the growth of the market over the forecast period of 2022-2028. Also, an increasing number of technological advancements is anticipated to act as a catalyzing factor for the market demand during the forecast period.

The key regions considered for the global Cartilage Repair/ Cartilage Regeneration Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the rising prevalence of musculoskeletal diseases, increasing research investments in the US and Canada, and the presence of major market players in the region. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the high burden of osteoarthritis, as well as the growing occurrence of sports injuries, would create lucrative growth prospects for the Cartilage Repair/ Cartilage Regeneration Market across the Asia-Pacific region.

SPECIAL OFFER (Avail an Up-to 30% discount on this report :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5129

Major market players included in this report are: Orthocell Ltd. Braun Melsungen Ag Arthrex, Inc. DePuy Synthes Company Smith & Nephew plc Zimmer Biomet Company Conmed Corporation Stryker Corporation Regrow Biosciences Pvt. Ltd. Vericel Corporation The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

Access full Report Description, TOC, Table of Figure, Chart, etc :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5129

By Treatment Modality:Cell-based Chondrocyte Transplantation Stem Cells Growth Factors Non-cell-based Tissue Scaffolds Cell-free Composites By Application:Hyaline Cartilage Fibrocartilage By Application Site:Knee Hip Ankle and Foot Other Application Sites By End User:Hospitals Ambulatory Surgery Centers and Clinics By Region:North America U.S. Canada Europe UK Germany France Spain Italy ROE

Asia Pacific China India Japan Australia South Korea RoAPAC Latin America Brazil Mexico Rest of the World

Table of Content

Access Full Report, here:-https://reportocean.com/industry-verticals/sample-request?report_id=bw5129

About Report Ocean: We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us: Report Ocean: Email:sales@reportocean.com Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE) Website:https://www.reportocean.com/

See original here:
Cartilage Repair/ Cartilage Regeneration Market 2022 Size, Competitive Landscape and Key Regions 2030 This Is Ardee - This Is Ardee

Turning Back the Clock on ALS Cells Reveals New Mechanism – Technology Networks

At the current time, there is no cure for amyotrophic lateral sclerosis (ALS). Things may be about to change, however. Researchers at FAU and the University of California San Diego (UCSD) have identified a protein that already displays pathological characteristics at an early stage of the neurological disease. The team has published their discovery, that could lead to a new approach for treating the disease, in the journal Acta Neuropathologica.

In summer 2014, amyotrophic lateral sclerosis, or ALS for short, received a lot of attention through a social media campaign. In the ice bucket challenge, millions of people across the globe emptied a bucket of ice cold water over their heads to simulate a feeling of paralysis due to the extreme cold. In Germany, approximately 6,000 to 8,000 people are living with ALS, and approximately 2,000 new cases of the disease, that proves fatal within just a few years, are diagnosed every year. ALS is a motor neuron disease, that means it damages the nerve cells that control our muscles, explains Prof. Dr. Beate Winner. During the first phase, muscles become weaker, before wasting away and finally leaving patients unable to swallow or breathe independently. The social media campaign was used to raise money for research into ALS.

Beate Winner is a professor for stem cell models for rare neural diseases at FAU, head of the Department of Stem Cell Biology, and speaker for the Center for Rate Diseases at Universittsklinikum Erlangen. Her laboratory investigates what triggers neurodegenerative diseases of the nervous system such as ALS in the hope of discovering new treatment options as a result. We have known for roughly 15 years that during the end stage of ALS, the protein TDP-43 found in neurons becomes insoluble and starts to form clumps, explains Winner. It loses its normal functions and adopts toxic properties. Even though these pathological changes are not yet noticeable in patients, the fate of the nerve cells is already sealed. Winner continues, We wanted to know whether we could find causes for ALS at an early stage of development before the TDP-43 changes.

She started her quest together with Prof. Dr. Jrgen Winkler and PD Dr. Martin Regensburger from the Department of Molecular Neurology at Universittsklinikum Erlangen. The researchers used an innovative technique. They extracted a small skin sample from the upper arm of ALS patients and healthy people in a control group and reprogrammed it into what are known as induced pluripotent stem cells, cells that are equivalent to a very early stage of human development and that can in theory develop into any cell within the human body. These stem cells were then transformed into nerve cells. Basically, we turned the clock back and generated neurons imitating the developmental stage of a fetus, explains Winner. The fact that cells from adult people can be reprogrammed back into pluripotent stem cells was discovered by Shinya Yamanaka, who received the Nobel Prize for Medicine in recognition of his work.

The Erlangen researchers searched for insoluble proteins in the cell samples using mass spectrometry, a high-throughput procedure. They were successful. In the nerve cells of ALS patients they discovered an RNA-binding protein named NOVA1. In the neurons, the protein demonstrated changes including a greatly increased degree of insolvency, but not yet the typical pathological characteristics of TDP-43, explains Dr. Florian Krach, member of the FAU team and lead author of the study. The cells in the control group did not display these changes.

Armed with these findings, Krach moved to the laboratory of the renowned RNA biologist and bioinformatics specialist Prof. Gene Yeo at the University of California in San Diego (USA), funded by the Bavaria California Technology Center (BaCaTeC). Thanks to specialized experiments and computer-assisted analysis he was able to investigate what NOVA1 binds to in RNA molecules and what influence it has on alternative splicing in human neurons. Alternative splicing is an extremely complex and ingenious mechanism that humans use to multiply their repertoire of proteins, explains Krach. Sections of an RNA messenger molecule are either cut or added, thereby hindering, extending or changing the function of proteins altogether.

It has been known for some time that the alternative splicing process is unregulated in ALS patients. It is also known that TDP-43 influences this process. The team of researchers from Erlangen suspected, however, that other RNA-binding proteins are responsible for the pathological processes in early stages of the disease before TDP-43 changes. This suspicion has now been confirmed with the discovery of the impaired functioning of NOVA1.

We have made a pioneering discovery, but it is only one first step towards possibly being able to detect ALS in the early stages, says Beate Winner. Follow-up studies with larger cohorts could deepen our understanding of the importance of RNA-binding proteins. The researchers hope that their work will help contribute to developing new therapy concepts before neurons cross the point of no return.

Reference:Krach F, Wheeler EC, Regensburger M, et al. Aberrant NOVA1 function disrupts alternative splicing in early stages of amyotrophic lateral sclerosis. Acta Neuropathol. 2022. doi:10.1007/s00401-022-02450-3

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the rest here:
Turning Back the Clock on ALS Cells Reveals New Mechanism - Technology Networks